Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Syros Pharmaceuticals
(NQ:
SYRS
)
0.2557
-0.0375 (-12.79%)
Streaming Delayed Price
Updated: 3:20 PM EST, Nov 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Syros Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Syros Announces First Patient in Dose Confirmation Study of SY-2101, a Novel Oral Form of Arsenic Trioxide, in Acute Promyelocytic Leukemia
September 29, 2021
From
Syros Pharmaceuticals
Via
Business Wire
Syros Reports Inducement Grant to Chief Commercial Officer under Nasdaq Listing Rule 5635(c)(4)
September 28, 2021
From
Syros Pharmaceuticals
Via
Business Wire
Syros Announces Appointment of Conley Chee as Chief Commercial Officer
September 27, 2021
From
Syros Pharmaceuticals
Via
Business Wire
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
August 18, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
August 17, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc...
Via
Benzinga
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
August 05, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (...
Via
Benzinga
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
July 28, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc...
Via
Benzinga
Exposures
COVID-19
12 Health Care Stocks Moving In Tuesday's Intraday Session
September 21, 2021
Gainers Corvus Pharmaceuticals (NASDAQ:CRVS) stock moved upwards by 30.95% to $8.08 during Tuesday's regular session. As of 12:30 EST, this security is trading at a...
Via
Benzinga
Syros Posts Updated Data From CDK7 Inhibitor In Various Solid Tumor Settings
September 20, 2021
Syros Pharmaceuticals Inc (NASDAQ: SYRS) announced new data from the dose-escalation portion of the Phase 1 clinical trial of SY-5609. Updated data demonstrated...
Via
Benzinga
Syros Presents New Data from Phase 1 Trial of SY-5609 and Details Three-Pronged Combination Strategy to Advance SY-5609 in Solid Tumors and Blood Cancer
September 20, 2021
From
Syros Pharmaceuticals
Via
Business Wire
48 Biggest Movers From Friday
September 20, 2021
Gainers Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) shares jumped 135.4% to settle at $5.32 on Friday. The stock possibly traded higher following favorable data results by...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
September 17, 2021
Gainers Corvus Pharmaceuticals (NASDAQ:CRVS
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
September 17, 2021
Gainers Corvus Pharmaceuticals (NASDAQ:CRVS) stock moved upwards by 53.98% to $3.48 during Friday's pre-market session. The company's market cap stands at $147.6...
Via
Benzinga
Syros to Present New Data from Phase 1 Clinical Trial of SY-5609 in Oral Presentation at ESMO Congress 2021
September 13, 2021
From
Syros Pharmaceuticals
Via
Business Wire
Syros Announces Appointment of Deborah Dunsire, M.D., to Its Board of Directors
September 10, 2021
From
Syros Pharmaceuticals
Via
Business Wire
Syros Announces First Patient Dosed in SELECT-AML-1 Trial of Tamibarotene in Combination with Venetoclax and Azacitidine in Newly Diagnosed Unfit AML
September 09, 2021
From
Syros Pharmaceuticals
Via
Business Wire
Looking Into Syros Pharmaceuticals's Return On Capital Employed
September 07, 2021
Benzinga Pro data, Syros Pharmaceuticals (NASDAQ:SYRS) reported Q2 sales of $5.16 million. Earnings fell to a loss of $26.14 million, resulting in a 24.85% decrease from last...
Via
Benzinga
Syros to Present at Upcoming Investor Conferences in September
September 07, 2021
From
Syros Pharmaceuticals
Via
Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
August 05, 2021
Gainers Ensysce Biosciences (NASDAQ:ENSC) shares rose 42.78% to $5.84 during Thursday's pre-market session. The company's market cap stands at $141.7 million....
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
August 20, 2021
On Friday morning, 155 companies achieved new lows for the year. Interesting Points: Marqeta (NASDAQ:MQ) was the largest firm on a market cap basis to set a new 52-...
Via
Benzinga
Syros Reports Second Quarter 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
August 05, 2021
From
Syros Pharmaceuticals
Via
Business Wire
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
August 20, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19) Alkermes plc (NASDAQ: ALKS...
Via
Benzinga
Exposures
COVID-19
Stocks That Hit 52-Week Lows On Tuesday
August 17, 2021
Tuesday morning, 282 companies set new 52-week lows. Key Facts: Alibaba Group Holding (NYSE:BABA) was the biggest company by market cap to set a new 52-week low....
Via
Benzinga
Syros Announces Agreement with Roche to Evaluate SY-5609 as Part of a Novel Combination for Treatment of Colorectal Cancer
August 05, 2021
From
Syros Pharmaceuticals
Via
Business Wire
Syros to Report Second Quarter 2021 Financial Results on Thursday, August 5, 2021
July 29, 2021
From
Syros Pharmaceuticals
Via
Business Wire
Stocks That Hit 52-Week Lows On Thursday
July 15, 2021
During the morning session on Thursday, 152 stocks hit new 52-week lows. Interesting Points: TotalEnergies (NYSE:TTE) was the biggest company by market cap to set a new 52...
Via
Benzinga
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
August 01, 2021
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results....
Via
Benzinga
Exposures
Product Safety
Stocks That Hit 52-Week Lows On Tuesday
July 27, 2021
During Tuesday's morning session, 216 companies made new 52-week lows. Noteworthy Points: Alibaba Group Holding (NYSE:BABA) was the largest firm by market cap...
Via
Benzinga
The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study
July 16, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 15) IVERIC bio, Inc. (NASDAQ:...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs
July 15, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14) Alexion Pharmaceuticals,...
Via
Benzinga
Topics
Product Recall
Exposures
Legal
Product Safety
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.